Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 547-557

  Bai, Yongrui ^a   Ye, Ming ^a   Cao, Hongbin ^a   Ma, Xiumei ^a   Xu, Yuejuan ^b   Wu, Bin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Cost effectiveness; Early breast cancer; Markov model; Radiotherapy

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHINESE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EARLY CANCER; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT DURATION;

BREAST NEOPLASMS; FEMALE; HEALTH RESOURCES; HUMANS; MARKOV CHAINS; MASTECTOMY, SEGMENTAL; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS;

EID: 84868206196     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2268-1     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Porter PL (2009) Global trends in breast cancer incidence and mortality. Salud Publica Mex 51(Suppl 2):s141-s146
3. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR et al (2006) Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer 119:1447-1454
4. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD et al (2008) Effects of reproductive and demographic changes on breast cancer incidence in China: A modeling analysis. J Natl Cancer Inst 100:1352-1360
5. Jin F, Devesa SS, Chow WH, Zheng W, Ji BT, Fraumeni JF Jr et al (1999) Cancer incidence trends in urban shanghai, 1972-1994: An update. Int J Cancer 83:435-440
6. Albert US, Altland H, Duda V, Engel J, Geraedts M, Heywang-Kobrunner S et al (2009) 2008 Update of the guideline: Early detection of breast cancer in Germany. J Cancer Res Clin Oncol 135:339-354
7. Wang K, Wu Y, Zheng D, Liao N (2005) NCCN breast cancer practice guidelines. J Evid Based Med 5:232-256
8. Fitzal F, Riedl O, Jakesz R (2009) Recent developments in breast-conserving surgery for breast cancer patients. Langenbecks Arch Surg 394:591-609
9. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232
10. Zielske SP, Spalding AC, Wicha MS, Lawrence TS (2011) Ablation of breast cancer stem cells with radiation. Transl Oncol 4:227-233
11. Lim M, Bellon JR, Gelman R, Silver B, Recht A, Schnitt SJ et al (2006) A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys 65:1149-1154
12. Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Iino Y et al (1995) Effects of radiotherapy and surgery in early breast-cancer-an overview of the randomized trials. N Engl J Med 333: 1444-1455
13. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25: 3259-3265
14. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER et al (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149
15. Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN et al (1996) Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet (North American Edition) 348:708-713
16. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M et al (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963-970
17. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351:971-977
18. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J et al (1994) Sector resection with or without postoperative radiotherapy for stage I breast cancer: Five-year results of a randomized trial. J Natl Cancer Inst (Bethesda) 86:717-722
19. Malmstrom P, Holmberg L, Anderson H, Mattsson J, Jonsson PE, Tennvall-Nittby L et al (2003) Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: A randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 39:1690-1697
20. Potter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B et al (2007) Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68:334-340
21. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM et al (1997) Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963-968
22. Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M et al (1993) Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 328:1587-1591
23. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Metaanalysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716
24. Bellon JR, Harris EE, Arthur DW, Bailey L, Carey L, Goyal S et al (2011) ACR appropriateness criteria(R) conservative surgery and radiation-stage I and II breast carcinoma: Expert panel on radiation oncology: Breast. Breast J 17:448-455
25. Hayman JA, Hillner BE, Harris JR, Weeks JC (1998) Costeffectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022-1029
26. Liljegren G, Karlsson G, Bergh J, Holmberg L (1997) The costeffectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol 8:757-763
27. Suh WW, Hillner BE, Pierce LJ, Hayman JA (2005) Costeffectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 61:1054-1061
28. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS et al (2006) Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12(Suppl 1):S3-S15
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717
30. Suen D, Chow L, Kwong A (2008) Breast-conserving surgery in Hong Kong Chinese women. World J Surg 32:2549-2553
31. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B et al (2004) Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. Am Fam Physician 69:548-556
32. Wilson DL (1994) The analysis of survival (mortality) data: Fitting Gompertz, Weibull, and logistic functions. Mech Ageing Dev 74:15-33
33. Schmoor C, Sauerbrei W, Bastert G, Schumacher M (2000) Role of isolated locoregional recurrence of breast cancer: Results of four prospective studies. J Clin Oncol 18:1696-1708
34. Rau KM, Li SH, Chen SM, Tang Y, Huang CH, Wu SC et al (2011) Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients. Jpn J Clin Oncol 41:455-461
35. Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q et al (2010) Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Chemotherapy 56:340-347
36. Yeo W,MokTS, Tse KK, KwanWH, LamKC, HoWMet al (2002) Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anticancer Drugs 13:655-662
37. Yeh KH, Lu YS, Hsu CH, Lin JF, Chao HJ, Huang TC et al (2005) Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer. Br J Cancer 92:1013-1018
38. Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: A final analysis. Jpn J Clin Oncol 37:23-29
39. Life tables for WHO Member States (2011) World Health Organization, Geneva. http://www.who.int/whosis/database/life-tables/life-tables.cfm. Accessed 12 Mar 2012
40. Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L et al (2009) Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics 27:873-886
41. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253-1258
42. Lidgren M, Wilking N, Jonsson B, Rehnberg C (2007) Health related quality of life in different states of breast cancer. Qual Life Res 16:1073-1081
43. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A (2007) Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess 11:1-144
44. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R et al (2010) gp120 Modulates the biology of human hepatic stellate cells: A link between HIV infection and liver fibrogenesis. Gut 59:513-520
45. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 7:518-528
46. Murray CJ, Evans DB, Acharya A, Baltussen RM (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9:235-251
47. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL et al (2011) A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 11:364
48. Lee JH, Glick HA, Hayman JA, Solin LJ (2002) Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol 20:2713-2725
49. Osteen RT, Karnell LH (1994) The National Cancer Data Base report on breast cancer. Cancer 73:1994-2000
50. Untch M (2011) Treatment of early breast cancer. Breast Care (Basel) 6:177
51. Lee SG, Jee YG, Chung HC, Kim SB, Ro J, Im YH et al (2009) Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: Docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat 114:589-595
52. Sculpher M (2008) Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 26:799-806
53. Delaney G (2005) Recent advances in the use of radiotherapy to treat early breast cancer. Curr Opin Obstet Gynecol 17:27-33